Protocol Reference — Cardiovascular Health

BPC-157 cycle

4–8 weeks on, minimum 4 weeks off

Standard-sensitivity protocol; prevents tachyphylaxis and limits cumulative pro-angiogenic exposure.

Thymosin β4 cycle

6–10 weeks on, off-cycle before resuming

Phase 2 trial duration is a reasonable upper bound for continuous dosing.

Elamipretide (SS-31)

Continuous daily dosing in clinical trials

Maintenance paradigm; not yet established whether off-cycles are needed in cardiovascular use.

Vesugen pulse

10–30 day course, 2–4 courses per year

Manufacturer-recommended pulse protocol; human clinical data limited.

Weekly schedule (Tβ4)

Twice weekly SubQ injection

Not daily — longer half-life supports intermittent dosing.

5/2 sensitivity rule

5 days on, 2 days off for continuous-dosed peptides

Standard practice to maintain receptor sensitivity.